Ying-Jia Ren1, Qing-Yun Zhang. 1. Department of Immunology, The School of Oncology, Peking University, Beijing Institute for Cancer Research, Beijing 100036, China.
Abstract
AIM: To investigate the expression of midkine in esophageal squamous cell carcinoma (ESCC) and analyze its relationship with clinicopathological features. METHODS: RT-PCR and immunocytochemical staining were used to detect the expression of midkine mRNA and protein in EC109 cells, respectively. Then the expression of midkine in 66 cases of ESCC samples were detected by immunohistochemistry using monoclonal antibodies against human midkine. RESULTS: Midkine was expressed in EC109 cell by RT-PCR and immunocytochemistry. The immunoreactivity was detected in 56.1% (37/66) of the ESCC samples. The expression of midkine was found in cytoplasm of tumor cells. Notably, the intensity of midkine was stronger at the area abundant in vessels and the invading border of the tumors. Midkine was more intensely expressed in well differentiated tumors (76.9%) than in moderately and poorly differentiated tumors (43.1% and 41.2%, respectively) (P<0.05). There was no statistically significant correlation between midkine expression and gender, age, clinical stage, lymph node metastasis or survival in ESCC. CONCLUSION: Midkine is overexpressed in ESCC. It may play a role in tumor angiogenesis and invasion. The expression of midkine is correlated with tumor cell differentiation in ESCC. The more poorly tumor cells differentiate, the weaker midkine expresses.
AIM: To investigate the expression of midkine in esophageal squamous cell carcinoma (ESCC) and analyze its relationship with clinicopathological features. METHODS: RT-PCR and immunocytochemical staining were used to detect the expression of midkine mRNA and protein in EC109 cells, respectively. Then the expression of midkine in 66 cases of ESCC samples were detected by immunohistochemistry using monoclonal antibodies against humanmidkine. RESULTS:Midkine was expressed in EC109 cell by RT-PCR and immunocytochemistry. The immunoreactivity was detected in 56.1% (37/66) of the ESCC samples. The expression of midkine was found in cytoplasm of tumor cells. Notably, the intensity of midkine was stronger at the area abundant in vessels and the invading border of the tumors. Midkine was more intensely expressed in well differentiated tumors (76.9%) than in moderately and poorly differentiated tumors (43.1% and 41.2%, respectively) (P<0.05). There was no statistically significant correlation between midkine expression and gender, age, clinical stage, lymph node metastasis or survival in ESCC. CONCLUSION:Midkine is overexpressed in ESCC. It may play a role in tumor angiogenesis and invasion. The expression of midkine is correlated with tumor cell differentiation in ESCC. The more poorly tumor cells differentiate, the weaker midkine expresses.
Authors: H Sakitani; M Tsutsumi; K Kadomatsu; S Ikematsu; M Takahama; K Iki; T Tsujiuchi; T Muramatsu; S Sakuma; T Sakaki; Y Konishi Journal: Carcinogenesis Date: 1999-03 Impact factor: 4.944
Authors: M Miyauchi; H Shimada; K Kadomatsu; T Muramatsu; S Matsubara; S Ikematsu; K Takenaga; T Asano; T Ochiai; S Sakiyama; M Tagawa Journal: Jpn J Cancer Res Date: 1999-04
Authors: S Maeda; H Shinchi; H Kurahara; Y Mataki; H Noma; K Maemura; K Aridome; T Yokomine; S Natsugoe; T Aikou; S Takao Journal: Br J Cancer Date: 2007-07-10 Impact factor: 7.640